Top Markets
#1 Black Phoenix Black Phoenix +166.52%
#2 Islamic Coin Islamic Coin +158.25%
#3 Glidr Glidr +84.34%
#4 Test Test +21.69%
#5 Cryptopia Cryptopia +21.17%
#6 Quantum Resistant Ledger Quantum Resistant Ledger +18.52%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.45%
#8 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +12.47%
#9 MarsCoin MarsCoin +11.59%
#10 DOVU DOVU +8.82%
Coin of the day
Black Phoenix Black Phoenix
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Arno Therapeutics, Inc. Arno Therapeutics, Inc.

Arno Therapeutics, Inc.

ARNI
Classement en actions #42094
Arno Therapeutics, Inc., headquartered in Flemington, New Jersey, operates as a... Arno Therapeutics, Inc., headquartered in Flemington, New Jersey, operates as a biopharmaceutical enterprise focused on discovering and advancing treatments for cancer and other severe health conditions. The company's developmental portfolio includes several key compounds: Onapristone, a type 1 anti-progestin hormone blocker, is currently undergoing Phase I/II clinical trials. This therapeutic is being investigated for its efficacy in treating various solid tumors, such as breast and endometrial cancers in post-menopausal women, and advanced castration-resistant prostate cancer in men. AR-12, an orally administered cancer therapy, has successfully completed Phase I clinical studies for solid tumors and hematological malignancies. Additionally, it is in pre-clinical development for potential applications against a range of microbial targets. AR-42, another innovative oral cancer treatment, is involved in a Phase I investigator-initiated clinical study, targeting both hematological malignancies and solid tumors. To support its research and development efforts, Arno Therapeutics has established licensing agreements with Invivis Pharmaceuticals, Inc., the Regents of the University of Minnesota, and the Ohio State University Innovation Foundation. The company also holds a co-development partnership with Leica Biosystems Newcastle Ltd.
Prix de l'action
$0.0001
Dernière synchronisation: 2026-08-11
Capitalisation boursière
$4.94K
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
US
Échange Arno Therapeutics, Inc. (ARNI)

Catégorie

Healthcare
Ratio P/B pour Arno Therapeutics, Inc. (ARNI)
Ratio P/B au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Arno Therapeutics, Inc., le ratio cours/valeur comptable actuel (TTM) est 0. À la fin de 2026, le ratio P/B était de 0.
Historique du ratio P/B pour Arno Therapeutics, Inc. de 2026 à 2026
Ratio P/B à la fin de chaque année
Année Ratio P/B Changez
Pas assez de données pour les dates fournies.
Ratio P/B pour des entreprises similaires ou concurrentes
Entreprise Ratio P/B Différence de Ratio P/B Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.2613 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.3483 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.634 -
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR